{"id":1010083,"date":"2026-10-14T08:34:58","date_gmt":"2026-10-14T12:34:58","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/"},"modified":"2026-10-14T08:34:58","modified_gmt":"2026-10-14T12:34:58","slug":"biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/","title":{"rendered":"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting"},"content":{"rendered":"
\n

CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company\u2019s ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson\u2019s Disease have been accepted for presentation at\u00a0ANA2026<\/a>, the annual meeting of the American Neurological Association.<\/p>\n

Results of the two studies will be presented as posters during the conference. ANA2026 will be held in San Diego, CA from October 17-20, 2026.<\/p>\n

\n Long COVID \u2014 ADDRESS-LC<\/strong>
\n
Title: Results of a Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)<\/em>
Authors: Penelope Markham (BioVie), Michael J. Peluso (UCSF), Christopher Reading (BioVie), Clarence Ahlem (BioVie), Stephen O\u2019Quinn (Perissos), Navid A. Samad (Samad Consulting), Jeffrey Zhang (Princeton Pharmatech), Joseph M. Palumbo (BioVie)
Date: Sunday, October 18, 2026; Time: 5:30\u20137:00 PM<\/p>\n

\n Parkinson\u2019s disease \u2014 SUNRISE-PD<\/strong>
\n
Title: Bezisterim (NE3107) in Early Parkinson\u2019s Disease (SUNRISE-PD):<\/em>
Initial Results and Observations from a Phase 2 Hybrid Design Trial<\/em>
Authors: Authors: Joseph Palumbo (BioVie); Clarence Ahlem (BioVie); Christopher L. Reading (BioVie); Stephen O\u2019Quinn (Perissos); Jeffrey Zhang (Princeton Pharmatech); Mark Stacy (Medical University of South Carolina)
Date: Monday, October 19, 2026; Time: 5:30\u20137:00 PM<\/p>\n

\n About Bezisterim<\/strong>\n <\/p>\n

Bezisterim (NE3107) is an investigational oral drug that crosses the blood-brain barrier and works to reduce inflammation and improve insulin sensitivity without suppressing the immune system and with a low risk of drug-drug interactions. By modulating key pathways involved in neuroinflammation (ERK, NF\u03baB, TNF\u03b1), bezisterim may have therapeutic potential in several disease indications, including Parkinson\u2019s disease (PD), Long COVID (LC), and Alzheimer\u2019s disease (AD).<\/p>\n

In PD, BioVie completed the SUNRISE-PD trial, which enrolled 57 patients to establish proof of mechanism and proof of concept in individuals with early-stage disease who had not previously been treated with carbidopa\/levodopa. Topline results showed that patients treated with bezisterim experienced improvements with blood-based markers of inflammation, as well as a broad range of biomarkers associated with cellular health and neuronal integrity. Clinically, patients treated with bezisterim demonstrated greater improvements than those receiving placebo across multiple measures of daily functioning, motor symptoms, and non-motor symptoms.<\/p>\n

For LC, the ADDRESS-LC trial enrolled approximately 200 patients to evaluate whether bezisterim may help reduce brain fog, fatigue, and other chronic neurological symptoms associated with LC. The hypothesis being studied is that these symptoms may be triggered by persistent circulation of spike protein fragments that trigger inflammation via NF\u03baB activation, a pathway that bezisterim has been shown to modulate.<\/p>\n

In AD, BioVie has conducted Phase 2 and Phase 3 trials. Preliminary data from these trials suggest improvements in cognition and biomarkers, supporting further trials to evaluate its potential as a therapy for the six million Americans living with AD.<\/p>\n

\n About BioVie Inc.<\/strong>\n <\/p>\n

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for neurological disorders and advanced liver disease. Its lead investigational drug candidate, bezisterim (NE3107), targets neuroinflammation and insulin resistance, which are believed to be key drivers of Alzheimer\u2019s and Parkinson\u2019s disease. Bezisterim is also being studied for Long COVID, where persistent inflammation is thought to underlie symptoms such as brain fog and fatigue.<\/p>\n

In liver disease, BioVie is advancing BIV201, a continuous infusion of terlipressin treatment that has received FDA Orphan and Fast Track designations. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis, and the Company plans to study BIV201 in a Phase 3 trial for the reduction of further decompensation in patients with cirrhosis and ascites. For more information, visit www.bioviepharma.com<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>\n <\/p>\n

This press release contains forward-looking statements, which may be identified by words such as “expect,” “look forward to,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “estimate,” “will,” “project,” \u201cpotential,\u201d \u201cmay,\u201d or words of similar meaning. Forward-looking statements in this release include, but are not limited to, statements regarding: the potential for bezisterim to address unmet clinical needs in Long COVID and Parkinson\u2019s disease; the design and conduct of future clinical trials, including a potentially pivotal Phase 3 trial; the potential clinical significance of subgroup analyses and biomarker observations; and the Company\u2019s ability to advance bezisterim through clinical development. The clinical endpoints reported in this release are exploratory in nature. The Phase 2 ADDRESS-LC trial did not achieve statistical significance on any endpoint in the overall intent-to-treat population; statistically significant results were observed only in pre-specified subgroup analyses. Subgroup analyses are hypothesis-generating and may not be replicated in future trials. Changes in biomarkers may not correlate with clinical benefit or support regulatory approval. The FDA has not validated these endpoints as surrogate endpoints for Long COVID. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to risks related to the early stage of development of bezisterim and other product candidates, the possibility that results observed in this Phase 2 study of 203 patients may not be replicated in larger or longer-duration trials, the exploratory nature of subgroup analyses, the Company’s ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, the possibility that clinical trial results may not be indicative of results in subsequent or larger trials, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company’s control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law.<\/p>\n

\n For Investor Relations Inquiries:<\/strong>
\n
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Contact:
Chuck Padala
Managing Director, LifeSci Advisors, LLC
chuck@lifesciadvisors.com<\/a><\/p>\n

\n For Media Inquiries:<\/strong>
\n
\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
Contact:
Melyssa Weible
Managing Partner, Elixir Health Public Relations
mweible@elixirhealthpr.com<\/a><\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company\u2019s ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson\u2019s Disease have been accepted for presentation at\u00a0ANA2026, the annual meeting of the American Neurological Association. Results of the two studies will be presented as posters during the conference. ANA2026 will be held in San Diego, CA from October 17-20, 2026. Long COVID \u2014 ADDRESS-LC Title: Results of a Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)Authors: Penelope Markham … <\/p>\n

Continue reading “BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1010083","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nBioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company\u2019s ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson\u2019s Disease have been accepted for presentation at\u00a0ANA2026, the annual meeting of the American Neurological Association. Results of the two studies will be presented as posters during the conference. ANA2026 will be held in San Diego, CA from October 17-20, 2026. Long COVID \u2014 ADDRESS-LC Title: Results of a Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)Authors: Penelope Markham … Continue reading "BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-10-14T12:34:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting\",\"datePublished\":\"2026-10-14T12:34:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/\"},\"wordCount\":1061,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/\",\"name\":\"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==\",\"datePublished\":\"2026-10-14T12:34:58+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting - Market Newsdesk","og_description":"CARSON CITY, Nev., Oct. 14, 2026 (GLOBE NEWSWIRE) — BioVie Inc. (NASDAQ: BIVI) (\u201cBioVie\u201d or the \u201cCompany\u201d), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that two abstracts detailing results from the Company\u2019s ADDRESS-LC Phase 2 trial in Long COVID, and SUNRISE-PD Phase 2 trial of bezisterim in Parkinson\u2019s Disease have been accepted for presentation at\u00a0ANA2026, the annual meeting of the American Neurological Association. Results of the two studies will be presented as posters during the conference. ANA2026 will be held in San Diego, CA from October 17-20, 2026. Long COVID \u2014 ADDRESS-LC Title: Results of a Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Bezisterim (NE3107) in Long COVID (ADDRESS-LC)Authors: Penelope Markham … Continue reading \"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2026-10-14T12:34:58+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting","datePublished":"2026-10-14T12:34:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/"},"wordCount":1061,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/","name":"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==","datePublished":"2026-10-14T12:34:58+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTg0NTAwMSM3ODkzOTExIzUwMDA3OTY2Ng=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biovie-to-present-new-bezisterim-findings-in-parkinsons-disease-and-long-covid-at-the-2026-american-neurological-association-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"BioVie to Present New Bezisterim Findings in Parkinson\u2019s Disease and Long COVID at the 2026 American Neurological Association Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010083","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1010083"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1010083\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1010083"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1010083"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1010083"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}